Burning Rock Biotech Limited (BNR) Income Statement
BNR 2025 at a glance
Fiscal year ended December 31, 2025 · Chinese yuanBNR revenue and net income
Where BNR's revenue goes
2025Each bar shows an amount and its share of revenue. BNR kept −10.3% of revenue as net income.
BNR profit margins
BNR growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +4.6% | −1.4% | +4.6% | — |
| Gross profit | +11.2% | +2.0% | +5.1% | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
BNR income statement in Chinese yuan
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥539.6M | CN¥515.8M | CN¥537.4M | CN¥563.2M | CN¥507.9M | CN¥429.9M | CN¥381.7M | CN¥208.9M | CN¥111.2M |
| Cost of revenue | CN¥136.7M | CN¥153.4M | CN¥174.2M | CN¥183.2M | CN¥143.7M | CN¥116.0M | CN¥108.3M | CN¥73.8M | CN¥39.5M |
| Gross profit | CN¥402.9M | CN¥362.4M | CN¥363.2M | CN¥380.0M | CN¥364.1M | CN¥313.9M | CN¥273.3M | CN¥135.1M | CN¥71.7M |
| Research & development | CN¥166.5M | CN¥232.3M | CN¥347.0M | CN¥421.9M | CN¥367.9M | CN¥263.9M | CN¥156.9M | CN¥105.3M | CN¥49.0M |
| Sales, general & admin | CN¥291.3M | CN¥452.5M | CN¥685.5M | CN¥938.6M | CN¥793.4M | CN¥462.4M | CN¥285.5M | CN¥191.2M | CN¥143.5M |
| Total operating expenses | CN¥457.8M | CN¥720.0M | CN¥1.03B | CN¥1.36B | CN¥1.16B | CN¥726.3M | CN¥442.4M | CN¥296.5M | CN¥192.6M |
| Operating income | −CN¥54.8M | −CN¥357.6M | −CN¥669.3M | −CN¥980.4M | −CN¥797.1M | −CN¥412.4M | −CN¥169.1M | −CN¥161.4M | −CN¥120.9M |
| Interest income | CN¥8.1M | CN¥12.2M | CN¥15.3M | CN¥9.5M | CN¥3.5M | CN¥6.1M | CN¥3.7M | CN¥15.6M | CN¥10.4M |
| Interest expense | CN¥30,000 | CN¥0 | CN¥0 | CN¥11.2M | CN¥1.5M | CN¥667,000 | CN¥9.0M | CN¥18.0M | CN¥9.9M |
| Income before taxes | −CN¥53.8M | −CN¥340.7M | −CN¥651.3M | −CN¥969.2M | −CN¥795.8M | −CN¥407.2M | −CN¥169.2M | −CN¥177.5M | −CN¥131.3M |
| Income taxes | CN¥1.6M | CN¥5.9M | CN¥2.4M | CN¥2.0M | CN¥899,000 | −CN¥33.5M | −CN¥819,000 | CN¥1.9M | CN¥10.4M |
| Net income | −CN¥55.3M | −CN¥346.6M | −CN¥653.7M | −CN¥971.2M | −CN¥796.7M | −CN¥407.2M | −CN¥168.3M | −CN¥177.5M | −CN¥131.3M |
| EBITDA | −CN¥32.0M | −CN¥270.2M | −CN¥517.9M | −CN¥845.2M | −CN¥746.5M | −CN¥373.3M | −CN¥128.8M | −CN¥135.9M | −CN¥99.6M |
| Gross margin | 74.7% | 70.3% | 67.6% | 67.5% | 71.7% | 73.0% | 71.6% | 64.7% | 64.5% |
| Operating margin | −10.2% | −69.3% | −124.5% | −174.1% | −156.9% | −95.9% | −44.3% | −77.3% | −108.7% |
| Net margin | −10.3% | −67.2% | −121.6% | −172.4% | −156.9% | −94.7% | −44.1% | −85.0% | −118.1% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥134.9M | CN¥107.9M | CN¥124.6M | CN¥131.6M | CN¥148.6M | CN¥133.1M | CN¥126.0M | CN¥128.6M | CN¥135.5M | CN¥125.6M | CN¥121.1M | CN¥127.6M |
| Cost of revenue | CN¥37.0M | CN¥29.9M | CN¥27.4M | CN¥32.8M | CN¥40.5M | CN¥35.7M | CN¥36.6M | CN¥36.8M | CN¥40.1M | CN¥39.9M | CN¥43.0M | CN¥41.6M |
| Gross profit | CN¥97.9M | CN¥78.0M | CN¥97.2M | CN¥98.8M | CN¥108.1M | CN¥97.4M | CN¥89.4M | CN¥91.8M | CN¥95.4M | CN¥85.7M | CN¥78.1M | CN¥85.9M |
| Research & development | CN¥31.3M | CN¥27.6M | CN¥34.4M | CN¥41.5M | CN¥49.8M | CN¥40.4M | CN¥52.2M | CN¥49.1M | CN¥65.0M | CN¥66.0M | CN¥73.1M | CN¥83.7M |
| Sales, general & admin | CN¥84.6M | CN¥69.3M | CN¥75.7M | CN¥73.5M | CN¥69.8M | CN¥72.2M | CN¥84.0M | CN¥81.3M | CN¥141.7M | CN¥145.5M | CN¥171.3M | CN¥181.0M |
| Total operating expenses | CN¥115.9M | CN¥96.9M | CN¥109.1M | CN¥115.0M | CN¥119.6M | CN¥112.6M | CN¥172.8M | CN¥130.4M | CN¥206.7M | CN¥211.5M | CN¥244.4M | CN¥264.7M |
| Operating income | −CN¥18.0M | −CN¥18.8M | −CN¥11.9M | −CN¥16.1M | −CN¥11.5M | −CN¥15.2M | −CN¥46.8M | −CN¥38.6M | −CN¥111.2M | −CN¥125.8M | −CN¥166.3M | −CN¥178.8M |
| Interest income | — | CN¥1.3M | CN¥1.5M | CN¥1.7M | CN¥2.2M | CN¥2.6M | CN¥1.8M | CN¥3.2M | CN¥3.2M | CN¥4.0M | CN¥5.5M | CN¥4.0M |
| Interest expense | CN¥15,016 | CN¥15,000 | CN¥14,792 | CN¥15,000 | — | CN¥0 | — | CN¥0 | — | — | — | — |
| Income before taxes | −CN¥18.1M | −CN¥17.2M | −CN¥14.3M | −CN¥16.5M | −CN¥9.5M | −CN¥13.3M | −CN¥76.0M | −CN¥35.5M | −CN¥107.8M | −CN¥121.4M | −CN¥161.1M | −CN¥174.5M |
| Income taxes | CN¥287,304 | CN¥232,000 | CN¥863,907 | CN¥212,000 | CN¥244,000 | CN¥224,000 | — | CN¥201,000 | CN¥190,000 | CN¥180,000 | CN¥1.1M | CN¥450,000 |
| Net income | −CN¥18.4M | −CN¥17.5M | −CN¥15.2M | −CN¥16.8M | −CN¥9.7M | −CN¥13.5M | −CN¥81.3M | −CN¥35.7M | −CN¥108.0M | −CN¥121.5M | −CN¥162.2M | −CN¥175.0M |
| EBITDA | −CN¥15.7M | −CN¥17.2M | −CN¥9.1M | −CN¥16.5M | CN¥3.4M | −CN¥13.3M | — | −CN¥2.7M | −CN¥107.8M | −CN¥88.5M | −CN¥147.8M | −CN¥144.3M |
| Gross margin | 72.6% | 72.3% | 78.0% | 75.1% | 72.8% | 73.2% | 71.0% | 71.4% | 70.4% | 68.2% | 64.5% | 67.4% |
| Operating margin | −13.4% | −17.5% | −9.5% | −12.3% | −7.7% | −11.4% | −37.1% | −30.0% | −82.1% | −100.2% | −137.4% | −140.2% |
| Net margin | −13.7% | −16.2% | −12.2% | −12.7% | −6.5% | −10.1% | −64.5% | −27.8% | −79.7% | −96.8% | −134.0% | −137.2% |
Quarterly columns are labeled by the month the quarter ended. Figures in Chinese yuan as reported in BNR's financial statements (latest annual report filed April 28, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
BNR financial results
In fiscal year 2025 (ended December 31, 2025), Burning Rock Biotech reported revenue of CN¥539.6 million, up 4.6% from the year before. It had a net loss of CN¥55.3 million, a net profit margin of −10.3%. Over five years revenue grew at an average rate of 4.6% a year. Figures are in Chinese yuan, the currency of its financial statements.
See the BNR stock overview for the latest quote and news, or the BNR chart for price history and technical indicators.
BNR income statement FAQ
What is Burning Rock Biotech's annual revenue?
Burning Rock Biotech reported total revenue of CN¥539.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 4.6% from CN¥515.8 million the previous year.
Is Burning Rock Biotech profitable?
No. Burning Rock Biotech reported a net loss of CN¥55.3 million in fiscal 2025, a net profit margin of −10.3%; its operating margin was −10.2%.
What is Burning Rock Biotech's gross margin?
Burning Rock Biotech's gross margin was 74.7% in fiscal 2025: for every $100 of revenue, Burning Rock Biotech kept $75 after the direct cost of its products and services.
How much does Burning Rock Biotech spend on research and development?
Burning Rock Biotech spent CN¥166.5 million on research and development in fiscal 2025, 30.9% of revenue.
How fast is Burning Rock Biotech growing?
Revenue grew 4.6% a year on average over the last five fiscal years, from CN¥429.9 million to CN¥539.6 million.
When will Burning Rock Biotech report its next earnings?
Burning Rock Biotech is expected to report results for the quarter ending September 30, 2026 on November 19, 2026.
When does Burning Rock Biotech's fiscal year end?
Burning Rock Biotech's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on April 28, 2026.